Thrombocytopenic Purpura
GSK initiates repeat dosing study of its novel oral platelet growth factor, eltrombopag, in ITP
Published in Medicine and Law Weekly, May 4th, 2007
GlaxoSmithKline plc today announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of eltrombopag in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP). The trial, called REPEAT (Repeat ExPosure to Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will evaluate a repeated dosing schedule of three six week cycles of eltrombopag treatment in 50 patients with chronic ITP who will be enrolled at multiple centres.
"The current treatment approaches to acutely increase the platelet count typically include treatment with steroids or IV gammaglobulin - both of which...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Epidemiology
Researchers at National Library of Medicine have published new data on epidemiology - Experimental Design
Study findings from University of Ioannina, Chemistry Department provide new insights into experimental design - Health Policy
Researchers at Johns Hopkins University release new data on health policy - Health Policy
Scientists at University of New England release new data on health policy - Life Sciences
New life sciences findings from Technical University of Denmark, Institute of Environment and Resources published - Life Sciences
Researchers from Charles River Laboratories discuss findings in life sciences - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
